Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
NSCLC, Stage III: full-pipeline trial registry
3 of 4 indexed NSCLC, Stage III trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
NSCLC, Stage III: 4 US clinical trials tracked, 3 recruiting.
NSCLC, Stage III is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Jun Zhang, MD, PhD, running 1 of these trials.
Enrollment posture brief
Registry condition nsclc-stage-iii
OPEN 3 | RECR 75% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
NSCLC, Stage III lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for NSCLC, Stage III on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
NSCLC, Stage III is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Maximilian Diehn
NCT04585490
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
Jun Zhang, MD, PhD
NCT04680377
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
University of Utah
NCT06945484
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT03999710
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on NSCLC, Stage III records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on NSCLC, Stage III trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this NSCLC, Stage III page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 NSCLC, Stage III trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jun Zhang, MD, PhD sponsors the most NSCLC, Stage III trials on record, review their full trial history before evaluating a specific study. See Jun Zhang, MD, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NSCLC, Stage III condition card totals 4 registered trials; most-linked intervention Durvalumab; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.